Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nicotine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 4/20 | 1.00 |
| ▸ | CHRNA4 known ✓ | P43681 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 4/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 3/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 3/20 | 1.00 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | PSIP1 | O75475 | 1/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 1/20 | 1.00 |
| ▸ | CHRNG | P07510 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 1/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | CHRNA5 | P30532 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+/-)Nicotine SCHEMBL20193 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| R-Nicotine SCHEMBL20518 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL10909351 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL308101 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL11976729 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL10909353 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL1724652 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL2599622 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL797620 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL407606 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106349665-A | Degradable biomedical materials added with poly-3-hydroxybutyrate and preparing method thereof | 胡何辉 | 2017-01-25 | — | — | CN | disclosed |
| US-20140155429-A1 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2706854-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH NICOTINE | Envivo Pharmaceuticals, Inc. (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20130324503-A1 | Method of identifying and treating a person having a predisposition to or afflicted with Parkinson disease | HEALTH RESEARCH INC. (US) | 2013-12-05 | — | — | US | disclosed |
| WO-2012154710-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH NICOTINE | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-7387788-B1 | Pharmaceutical compositions of nicotine and methods of use thereof | ANTARES PHARMA IPL AG (CH) | 2008-06-17 | — | — | US | disclosed |
| WO-2008012071-A2 | PHARMACEUTICAL COMPOSITIONS OF NICOTINE AND METHODS OF USE THEREOF | ANTARES PHARMA IPL AG (CH) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155429-A1 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine | CHRNA7, CHRNA10, CHRNA5 | CHRNB2 10/4885CHRNA4 5/4885ALDH1A1 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.